SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

AM095

Item No. 22141



CAS Registry No.:	1228690-36-5
Formal Name:	4'-[3-methyl-4-[[[(1R)-1-phenylethoxy] carbonyl]amino]-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid
MF:	$C_{27}H_{24}N_2O_5$
FW:	456.5
Purity:	≥95%
UV/Vis.:	λ_{max}: 297 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AM095 is supplied as a crystalline solid. A stock solution may be made by dissolving the AM095 in the solvent of choice, which should be purged with an inert gas. AM095 is soluble in the organic solvent DMSO.

Description

AM095 is an orally bioavailable antagonist of lysophosphatidic acid receptor 1 (LPA_1) with IC_{50} values of 25 and 23 nM in CHO cells expressing human or mouse receptors, respectively.[1] It is selective for LPA_1 over LPA_2, LPA_3, LPA_4, and LPA_5 (IC_{50}s = >10,000 nM for human LPA_{2-5}). It inhibits chemotaxis of CHO cells overexpressing LPA_1 and of A2058 human melanoma cells (IC_{50}s = 778 and 233 nM, respectively) and prevents LPA-induced increases in plasma histamine levels in mice (ED_{50} = 8.3 mg/kg).[2] It also decreases collagen and protein levels in bronchoalveolar lavage fluid (BALF) in a mouse model of bleomycin-induced lung injury (ED_{50}s = ~10 mg/kg for both) and decreases kidney fibrosis in a mouse model of unilateral ureteral obstruction when administered at a dose of 30 mg/kg for eight days.

References

1. Castelino, F.V., Seiders, J., Bain, G., *et al.* Genetic deletion or pharmacologic antagonism of LPA_1 ameliorates dermal fibrosis in a scleroderma mouse model. *Arthritis Rheum.* **63(5)**, 1405-1415 (2011).
2. Swaney, J.S., Chapman, C., Correa, L.D., *et al.* Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. *J. Pharmacol. Exp. Ther.* **336(3)**, 693-700 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM